ClinicalTrials.gg
RecruitingNCT06243172Cir-D-BrainUpdated Nov 7, 2024

Determining Circadian Metabolic and Behavioural Rhythms in Patients with and Without Type 2 Diabetes

An observational study in Type 2 Diabetes and Circadian Rhythm, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Steno Diabetes Center Copenhagen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
60
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 8 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.

Started
2024
with 3 others
Observational
6 of 31
3 open now
Registered
21st of 31
by date

Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one is one of 4 that started in 2024, is one of 6 observational ones, and was the 21st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, or all of them as a file.
02

Study summary

The goal of the present clinical descriptive study is to characterize and quantify the potential hormonal chronobiological differences between individuals with type 2 diabetes (T2D) and healthy age and weight-matched controls as either circadian aligned or misaligned. The investigators hypothesize that individuals with T2D have a misaligned and different circadian rhythmicity of circadian biomarkers (melatonin and cortisol) than controls, and that this difference in turn is related to 24h hormonal fluctuations, behaviour, and metabolic-, cardiac-, and cognitive parameters.

Participants will be asked to:

  • fill-out a diary on eating and sleeping habits for 30 days
  • wear an actigraphy and continuous glucose monitor for 10-14 days
  • stay overnight at the research facility, including continuous blood sampling and polysomnography
Read the detailed description

T2D is associated with cognitive dysfunction and an increased risk of developing dementia. This negative effect on cognition is worsened by T2D duration, yet the mechanisms are unknown.

Sleep disturbances increase peripheral insulin resistance, and is associated with the development of T2D, temporarily worsened cognitive function, and the development of cognitive impairment. In turn, T2D is associated with circadian misalignment (a condition where the internal physiological clock is unaligned with the external behavior). A major external signal (also known as zeitgeber) for synchronizing the internal and external clock is sleep in accordance with the day-night cycle.

Determining the circadian rhythm of an individual and whether it is aligned or misaligned is complex and can't be done by one measurement. However, melatonin and cortisol are often used as "circadian biomarkers" due to significant and well-defined circadian rhythm profiles. Another measure of the circadian phase is the timing of melatonin production under dim light conditions (dim light melatonin onset) which is an individual phase marker depending on the persons habitual time of sleep. Most studies focusing on circadian alignment in an everyday setting have used questionnaires, and to our knowledge, no studies have described 24-h circadian oscillations between individuals with T2D and healthy age and weight matched controls. Mapping these potential differences could help explain the pathophysiological mechanisms behind T2D and circadian misalignment.

The Cir-D-Brain study is a clinical descriptive study. The study comprises of an information visit, a screening visit, a midway visit (2 weeks after screening), a 24-h in-hospital day (a day between the midway visit and the final visit), and a final visit (2 weeks after the midway visit). Participants will keep a diary on eating and sleeping habits for all 30 days. At the midway visit, participants will be equipped with an actigraphy and a continuous glucose monitor. At the 24-h in-hospital day, participants will have their blood sampled every third hour for 24 hours to measure their circadian rhythm, every hour from 6 pm till 12 am to map dim light melatonin onset, and at wake-up to map cortisol awakening response. At the 24-h in-hospital day, participants will furthermore have their sleep stages measured by polysomnography. The study will include 30 participants with T2D and 30 age and BMI matched controls.

The specific objectives are:

  1. To characterize and quantify the hormonal chronobiological differences between individuals with T2D and healthy matched controls measured by circadian biomarkers.
  2. To relate the findings to 24-h hormonal fluctuations, different patterns in metabolism, behavioural circadian rhythms differences (sleep-wake and eating habits), sleep stages, glycaemic variability, inflammation, heart rate variability, and cognition.
03

Conditions studied

  • Type 2 Diabetes
  • Circadian Rhythm

Keywords

  • Type 2 Diabetes
  • Circadian Rhythm
  • Cognition
  • Sleep
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Primary care clinic, Steno Diabetes Center Copenhagen out-patient clinic, community sample

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals with T2D:

  • Informed and written consent.
  • Clinically diagnosed diabetes mellitus type 2 for at least 5 years (diagnosed according to criteria of World Health Organization (WHO)).
  • >53 mmol/mol
  • Stable medical treatment for at least 8 weeks.
  • Plasma ≥8.00 mmol/L (male) or ≥6.4 mmol/L (female).
  • Male or female participants aged 50-75 years.

Healthy matched controls:

  • Informed and written consent.
  • Normal haemoglobin ≥8.00 mmol/L (male) or ≥6.4 mmol/L (female).
  • Male or female participants aged 50-75 years.

Exclusion criteria

Exclusion Criteria:

  • (BMI) \<23 kg/m2
  • Receipt of any medicinal product within 3 months before screening in this trial.
  • Inability to perform neuropsychological tests (e.g., visual impairment or auditory impairment, or language barrier).
  • Participants with mental incapacity or language barriers precluding adequate understanding or co-operation or who, in the opinion of the investigator or their general practitioner, should not participate in the trial.
  • Prior or contemporary use of any kind of hypnotica within 6 months, former p.n. use of melatonin is judged by the investigator.
  • Nightshift-worker.
  • Known dementia or any other major disorders that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety.
  • Diagnosed sleep disorders (e.g., sleep apnoea and narcolepsy).
  • Significant history of alcoholism or drug/chemical abuse as per investigator's judgement.
  • Severe hypoglycaemic event during the past 6 months requiring medical assistance.
  • Diagnosed diabetic retinopathy.
  • Severe renal insufficiency defined as estimated (eGFR) ≤ 30 ml/min/1.73m2 or any kind of kidney disease that in the opinion of the investigator involves an unnecessary risk for the participants.
  • Cardiac problems including any of the following:

    1. Classified as being in (NYHA) class III or IV.
    2. Angina pectoris (chest pain) within the last 6 months.
  • Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the rage 90-150 mmHg for systolic and 50-100 mmHg for diastolic blood pressure.
  • Known lung disease that in the opinion of the investigator represents an unacceptable risk for the participant's safety.
  • Active or recent (≤ 12 months) malignant disease is judged by the investigator.
  • For females only: Pregnancy, breast-feeding status, or intention of becoming pregnant during the trial.
  • For healthy matched controls: prediabetes defined as between 42-47 mmol/mol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Type 2 Diabetes

    Individuals with type 2 diabetes

  • Controls

    Individuals without type 2 diabetes matched on age and body mass index

06

What researchers measure

Primary outcomes

  1. Melatonin oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

  2. Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

Secondary outcomes

  1. Dim light melatonin onset

    Blood samples (pg/ml)

    Time frame: 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)

  2. Phase angle (time between dim light melatonin onset and sleep)

    Blood samples

    Time frame: 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)

  3. Cortisol awakening response

    Blood samples (pg/ml)

    Time frame: 24-hour in-hospital day, blood samples taken at wake up, and 15-, 30-, and 60-minutes post-wake up

  4. Diary on sleeping habits

    Expanded Consensus Sleep Diary (time in bed, time to fall asleep, number of awakenings and durations, time of final awakening, time to get out of bed, total sleep time, sleep quality, daytime sleepiness, number of naps and duration, number and last time of alcohol consumption, number and last time of coffein consumption, use of sleep medicine)

    Time frame: 30 days

  5. Diary on eating window

    The eating window (initiation of first consumption and termination of last consumption of food)

    Time frame: 30 days

  6. Glycaemic variability

    Continuous glucose monitor (amplitude (mmol/L), frequency, and duration of the fluctuation, mean glucose (mmol/L), time in range, time in hyperglycemic and hypoglycemic range, area under the curve)

    Time frame: 10-14 days

  7. Sleep and waking states

    Actrigraph worn on the wrist of the non-dominant hand (acceleration at different times)

    Time frame: 10-14 days

  8. Heart rate variability (fluctuations in time intervals between adjacent heart beats)

    Measured continuously by the polysomnograph (ms)

    Time frame: 24-hour in-hospital day

  9. Sleep architecture

    Polysomnography (minutes and percentages). Sleep stages (N1, N2, N3, rapid eye movement (REM)), total time asleep, sleep latency, REM sleep latency, arousals, awakenings, total sleep efficiency.

    Time frame: 24-hour in-hospital day

  10. Cognition (verbal memory)

    Rey Auditory Verbal Learning Test (RAVLT)

    Time frame: 24-hour in-hospital day

  11. Cognition (psychomotor speed and executive function)

    Trail Making Test (TMT) part A and B ), Symbol Digit Modalities Test (SDMT)

    Time frame: 24-hour in-hospital day

  12. Cognition (executive function)

    WAIS-III Letter-Number Sequencing test, Verbal fluency test (letters S and D)

    Time frame: 24-hour in-hospital day

  13. Cognition (sustained attention)

    Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB)

    Time frame: 24-hour in-hospital day

  14. Cognition (verbal IQ)

    Danish Adult Reading Test (DART) (equivalent to the National Adult Reading Test; NART)

    Time frame: 24-hour in-hospital day

  15. Insulin oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples.

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

  16. C-peptide oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples.

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

  17. TSH oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples.

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

  18. Glucose oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples.

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

  19. Glucagon oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples.

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

  20. Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU))

    Blood samples.

    Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)

Other outcomes

  1. Chronotype (diurnal preference)

    Morningness-Eveningness Questionnaire (scoring)

    Time frame: At screening

  2. Sleep apnea

    Apnea-hypopnea index (events/hour)

    Time frame: 24-hour in-hospital day

  3. Blood pressure variations

    Measured continuously by the polysomnograph (mmHg)

    Time frame: 24-hour in-hospital day

  4. Cardiovascular autonomic neuropathy

    Assessed from three standard cardiovascular autonomic reflex tests: lying-to-standing test, deep breathing test, and Valsalva manoeuvre

    Time frame: At screening

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for May 2025, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2024
First posted
Feb 6, 2024
StartActual
Feb 1, 2024
Primary completionEst.
May 1, 2025
CompletionEst.
May 1, 2025
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06243172
Collaborators
Glostrup University Hospital, Copenhagen, University Hospital Bispebjerg and Frederiksberg
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Feb 1, 2024
Primary completion
May 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Nov 7, 2024

Study contacts

Helena Z Wodschow, MD
Contact
helena.zander.wodschow.03@regionh.dk
+45 30313426
Jørgen Rungby, MD, DMSc
Contact
joergen.rungby@regionh.dk
+45 21686620
Jørgen Rungby, MD, DMSc
principal investigator · Steno Diabetes Center Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion